IBJNews

Lilly lung cancer drug raises patient survival in trial

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co.’s experimental lung cancer medicine increased survival among patients compared with those on chemotherapy alone.

Shares in the Indianapolis-based drugmaker rose as much as 5.5 percent Tuesday morning after the announcement.

The drug, called necitumumab, met the primary endpoint of increasing overall survival in a trial involving 1,093 patients with non-small cell lung cancer whose disease had spread, the company said in a statement. Necitumumab was tested in patients with a type of tumor known as squamous cell carcinoma.

If approved, the drug would be a potent boost to Lilly’s product portfolio. It would also mean a critical new therapy for a cancer that’s proven difficult to treat with drugs such as Avastin that directly target tumors, as opposed to more broadly active chemotherapy drugs.

“This is a clear upside surprise,” Mark Schoenebaum, an analyst with ISI Group LLC, said in a note to clients.

Next year, Lilly plans to release full results from the study at a scientific meeting and anticipates submitting it to regulatory authorities. Non-small cell lung cancer accounts for about 85 percent of lung cancer, and patients with squamous cell carcinoma make up about 30 percent of those patients. Lung cancer is the leading cause of cancer death in the U.S.

“If apprved, necitumumab could be the first biologic therapy indicated to treat patients with squamous lung cancer,” Richard Gaynor, vice president, product development and medical affairs for Lilly Oncology, said in a prepared statement.

Lilly shares were up 4.4 percent, to $55.93 each at 10:46 a.m. The shares have gained 26 percent in the last 12 months as of Monday’s close.

Analysts had “basically zero” expectations for necitumumab, Schoenebaum said in his note. The drug failed in a prior non-squamous lung cancer trial, he said.

“We really need to see the full data to understand risk/benefit,” Schoenebaum said.

The most common adverse events seen in the study included rash. Less frequent, yet serious, side effects included blood clotting, Lilly said.

 

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. The $104K to CRC would go toward debts service on $486M of existing debt they already have from other things outside this project. Keystone buys the bonds for 3.8M from CRC, and CRC in turn pays for the parking and site work, and some time later CRC buys them back (with interest) from the projected annual property tax revenue from the entire TIF district (est. $415K / yr. from just this property, plus more from all the other property in the TIF district), which in theory would be about a 10-year term, give-or-take. CRC is basically betting on the future, that property values will increase, driving up the tax revenue to the limit of the annual increase cap on commercial property (I think that's 3%). It should be noted that Keystone can't print money (unlike the Federal Treasury) so commercial property tax can only come from consumers, in this case the apartment renters and consumers of the goods and services offered by the ground floor retailers, and employees in the form of lower non-mandatory compensation items, such as bonuses, benefits, 401K match, etc.

  2. $3B would hurt Lilly's bottom line if there were no insurance or Indemnity Agreement, but there is no way that large an award will be upheld on appeal. What's surprising is that the trial judge refused to reduce it. She must have thought there was evidence of a flagrant, unconscionable coverup and wanted to send a message.

  3. As a self-employed individual, I always saw outrageous price increases every year in a health insurance plan with preexisting condition costs -- something most employed groups never had to worry about. With spouse, I saw ALL Indiana "free market answer" plans' premiums raise 25%-45% each year.

  4. It's not who you chose to build it's how they build it. Architects and engineers decide how and what to use to build. builders just do the work. Architects & engineers still think the tarp over the escalators out at airport will hold for third time when it snows, ice storms.

  5. http://www.abcactionnews.com/news/duke-energy-customers-angry-about-money-for-nothing

ADVERTISEMENT